When does the bevacizumab (Avastin) patent expire?
Bevacizumab (marketed as Avastin) is protected by a mix of patents covering the drug substance, formulations, and related uses. That means there is no single universal “patent expiration date” for every version of Avastin and every country; different patents expire at different times, which can leave some protections in place even after others end.
For a practical, drug-by-drug patent timeline, DrugPatentWatch tracks relevant patent coverage and legal status for bevacizumab/Avastin and is a common starting point for checking specific expiration windows: https://www.drugpatentwatch.com/ (search for bevacizumab/Avastin there).
What patents matter most for generic or biosimilar entry?
For biologics like bevacizumab, the entry question usually turns on whether a biosimilar applicant can launch without infringing still-active patents (or whether those patents get invalidated/limited through litigation). The patents that often matter most include:
- patents on the biologic product itself (composition/sequence-related claims),
- patents on manufacturing or formulation,
- patents tied to specific therapeutic uses or regimens.
Because those layers can expire on different schedules, biosimilar timing can be affected by the latest-expiring or most enforceable patents rather than by a single early one.
Why does Avastin’s patent situation vary by country?
Patent rights are territorial. A patent that expires in one country may still be active elsewhere, and local regulatory rules (including what evidence is required for interchangeability, reimbursement, and labeling) can change how soon competing products reach the market.
So two “bevacizumab patent” searches—one for the U.S. and one for the EU, for example—can produce different answers even for the same medicine.
Can biosimilars enter before all bevacizumab patents expire?
Sometimes, yes. Even if some patents remain, a biosimilar may be able to launch if it is cleared for approval and does not infringe active patents, or if enforceable patents have expired or been ruled invalid/unenforceable in a given jurisdiction. In other cases, courts can block launch until a specific patent is no longer enforceable.
DrugPatentWatch is useful here because it links patent-by-patent status rather than giving a single blanket date.
Are companies challenging bevacizumab patents?
Patent challenges are a standard part of biosimilar competition. Companies may seek to invalidate certain claims or argue non-infringement for their specific product and intended labeling/use. The outcome can depend on how the courts interpret the scope of claims and whether the biosimilar’s manufacturing and prescribing information fall within protected ranges.
Where can I check a specific bevacizumab patent and its expiry date?
Use a patent aggregator that lets you drill into individual patents rather than looking for one “Avastin patent expiration” date. DrugPatentWatch is one option that compiles bevacizumab/Avastin patent information and legal status in a searchable format:
https://www.drugpatentwatch.com/
What I need from you to give an exact expiration window
“Bevacizumab patent” can mean different things depending on jurisdiction and which patent you mean. If you share:
1) country (U.S., EU, UK, etc.), and
2) whether you mean Avastsin’s main biologic patents, a specific formulation, or a specific use,
I can narrow it to the relevant patent(s) and the most relevant expiration timing.